Tag: equity
-
Company Helps Labs Build Gene, Cell Therapy Businesses
A new company formed offering full-scale facilities to develop cell and gene therapy products spun-off from academic research labs.
-
Infographic – Machine Learning Grabs Most A.I. Investments
So far this year, machine learning applications and platforms are gaining the most investment dollars worldwide for A.I., this weekend’s infographic.
-
Companies Partner on Kidney Disease in $2B Deal
A collaboration between biopharmaceutical maker Gilead Sciences and biotechnology company Goldfinch Bio aims to develop precision medicines for treating various kidney diseases.
-
Start-Up to Use Crispr for Heart Disease, Gains $59M
A new biotechnology enterprise plans to apply genetic analysis and the gene-editing technology Crispr to reduce the risk of coronary artery disease.
-
Synthetic Soft Tissue Developed for Surgery
Researchers developed a synthetic soft tissue for plastic and reconstructive surgery that in animal tests looks and performs more like real tissue.
-
Infographic – Venture Deals Cool Off in Q1 2019
Venture capital investments worldwide declined in the first quarter of 2019, compared to the near record-setting pace of the last 3 months of 2018.
-
Biotechs Partner on Gene Silencing in $1.1B Deal
Two biotechnology companies plan to develop new therapies mainly for eye and neurological diseases that silence genes responsible for those conditions.
-
Radiation-Antibody Biotech Raises $105M in Venture Funds
A company creating cancer treatments that combine radiation therapy with the targeting of synthetic antibodies is raising $105 million in its second round of venture financing.
-
Genome Editing Biotech Raises $126M in IPO
A biotechnology company developing treatments for disease and enhanced agricultural products with genome editing is raising $126 million in its initial public offering, or IPO, of common stock.
-
Respiratory Vaccine Maker Raises $3.4M in Seed Funds
A company developing vaccines that protect against respiratory diseases in vulnerable populations is raising new seed funds to advance its lead product into clinical trials.